Literature DB >> 2507570

Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.

M Kappy1, T Stuart, A Perelman, R Clemons.   

Abstract

The GnRH analog leuprolide acetate has been shown to be effective in the treatment of precocious puberty when given as a daily sc injection. We studied the effectiveness of a single im dose of a new depot form of leuprolide in suppressing estradiol and gonadotropin secretion in children with precocity. Five girls with previously untreated precocity showed significant decreases in basal serum estradiol and FSH levels and in peak LH levels (after GnRH testing) 30 days after a single im dose of leuprolide acetate for depot suspension. Mean peak FSH levels also fell greatly, but the difference was not significant. No adverse effects were noted during the first 4-6 months of monthly im injections. Depot im leuprolide appears to be effective in suppressing estradiol and gonadotropin secretion, and may be a useful method of treating children with central precocious puberty.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507570     DOI: 10.1210/jcem-69-5-1087

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Non-invasive delivery strategies for biologics.

Authors:  Aaron C Anselmo; Yatin Gokarn; Samir Mitragotri
Journal:  Nat Rev Drug Discov       Date:  2018-11-30       Impact factor: 84.694

Review 2.  Drug treatment in precocious puberty.

Authors:  M D Wheeler; D M Styne
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 3.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 4.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

5.  Surface analysis of PEGylated nano-shields on nanoparticles installed by hydrophobic anchors.

Authors:  M F Ebbesen; B Whitehead; B Ballarin-Gonzalez; P Kingshott; K A Howard
Journal:  Pharm Res       Date:  2013-04-12       Impact factor: 4.200

Review 6.  Degradable polymeric vehicles for postoperative pain management.

Authors:  Natasha C Brigham; Ru-Rong Ji; Matthew L Becker
Journal:  Nat Commun       Date:  2021-03-01       Impact factor: 14.919

7.  Effectiveness of Puberty Suppression with Gonadotropin-Releasing Hormone Agonists in Transgender Youth.

Authors:  Juan Diego Mejia-Otero; Perrin White; Ximena Lopez
Journal:  Transgend Health       Date:  2021-02-15

Review 8.  An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment.

Authors:  Frederick S vom Saal; Claude Hughes
Journal:  Environ Health Perspect       Date:  2005-08       Impact factor: 9.031

9.  Involvement of gonadotropin-inhibitory hormone in pubertal disorders induced by thyroid status.

Authors:  Mika Kiyohara; You Lee Son; Kazuyoshi Tsutsui
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.